metastatic urothelial carcinoma; immunotherapy; targeted therapy

von der Maase H, Sengelov L, Roberts JT, et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with metho-trexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer[J]. J Clin Oncol, 2005, 23(21):4602-4608. Bellmunt J, von der MaaseH, Mead GM, et al. Randomized phase Ⅲ study comparing paclitax-el/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987[J]. J Clin Oncol, 2012, 30(10):1107-1113. Bellmunt J, de Wit R, Vaughn DJ, et al. Pembroli-zumab as Second-Line Therapy for Advanced Urothelial Carcinoma[J]. N Engl J Med, 2017, 376(11):1015-1026. Rosenberg JE, Hoffman-Censits J, Powles T, et al. Atezoli- zumab in patients with locally advanced and metastatic uroth- elial carcinoma who have progressed following treatment with plati-num-based chemotherapy: a single-arm, multicen-tre, phase 2 trial[J]. Lancet, 2016, 387(10031):1909-1920. Powles T, Durán I, van der Heijden MS, et al. Ate-zolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial[J]. Lancet, 2018, 391(10122):748-757. Sharma P, Callahan MK, Bono P, et al. Nivolumab monotherapy in recurrent metastatic urothelial car-cinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial[J]. Lancet Oncol, 2016, 17(11):1590-1598. Sharma P, Retz M, Siefker-Radtke A, et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial[J]. Lancet Oncol, 2017, 18(3):312-322. Massard C, Gordon MS, Sharma S, et al. Safety and Efficacy of Durvalumab (MEDI4736), an An-ti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients with Advanced Urothelial Bladder Cancer[J]. J Clin Oncol, 2016, 34(26):3119-3125. Apolo AB, Infante JR, Balmanoukian A, et al. Avelumab, an Anti-Programmed Death-Ligand 1 Antibody, In Patients with Refractory Metastatic Urothelial Carcinoma: Results from a Multicenter, Phase Ⅰ b Study[J]. J Clin Oncol, 2017, 35(19): 2117-2124. Prendergast GC, Malachowski WP, DuHadaway JB, et al. Discovery of IDO1 Inhibitors: From Bench to Bedside[J]. Cancer Res, 2017, 77(24):6795-6811. Josep T. BMS-986205, an indoleamine 2,3-dioxygenase 1 inhibitor (IDO1i), incombina-tion with nivolumab (NIVO): Updated safety across all tumor cohortsand efficacy in pts with ad-vanced bladder cancer (advBC)[C]. Chicago: AS-CO, 2018. Smith DC, Gajewski T, Hamid O, et al. Epacadostat plus pembrolizumab in patients with advanced urothelial carcinoma: Preliminary phase Ⅰ / Ⅱ results of ECHO-202/KEYNOTE-037[C]. Chicago: ASCO, 2017 Balar AV, Castellano D, O'Donnell PH, et al. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study[J]. Lancet Oncol, 2017, 18(11):1483-1492. Balar AV, Galsky MD, Rosenberg JE, et al. Ate-zolizumab as first-line treatment in cispla-tin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, mul-ticentre, phase 2 trial[J]. Lancet, 2017, 389(10064):67-76. Tomlinson DC, Baldo O, Hamden P, et al. FGFR3 protein expression and its relationship tomutation status and prognostic variables in bladder cancer[J]. J Pathol, 2007, 213(1):91-98. Robertson AG, Kim J, Al-Ahmadie H, et al. Com-prehensive Molecular Characterization of Mus-cle-Invasive Bladder Cancer[J]. Cell, 2017, 171(3):540-556.e25. Arlene O. First results from the primary analysis population of the phase 2 study of erdafitinib (ERDA; JNJ-42756493) in patients (pts) with meta-static or unresectable urothelial carcinoma (mUC) and FGFR alterations (FGFRalt)[C]. Chicago: AS-CO, 2018. Markus J. Rogaratinib in patients with advanced urothelial carcinomas prescreened for tumor FGFR mRNA expression and effects of mutations in the FGFR signaling pathway[C]. Chicago: ASCO, 2018. Pal SK, Rosenberg JE, Keam B, et al. Efficacy of BGJ398, a fibroblast growth factor receptor (FGFR) 1-3 inhibitor, in patients (pts) with previously treated advanced/metastatic urothelial carcinoma (mUC) with FGFR3 alterations[C]. Chicago: ASCO, 2016. Jonathan ER. Updated results from the enfortumab vedotin phase 1 (EV-101) study in patients with metastatic urothelial cancer (mUC)[C]. Chicago: ASCO, 2018. Tagawa ST, Ocean AJ, Lam ET, et al. Therapy for chemopr- etreated metastatic urothelial cancer (mUC) with the antibody- drug conjugate (ADC) sacituzumabgovitecan (IMMU-132)[C]. Chicago: ASCO, 2017. Bellmunt J. Antiangiogenesis to curb urothelial cancer[J]. Lancet, 2017, 390(10109):2220-2221. Petrylak DP, de Wit R, Chi KN, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 tri-al[J]. Lancet, 2017, 390(10109):2266-2277. Nobuaki Matsubara. A subgroup analysis of the East Asia population in RANGE: A randomized phase 3 study of docetaxel (DOC) with or without ramucirumab (RAM) in platinumr- efractory ad-vanced or metastatic urothelial carcinoma (UC)[C]. Chicago: ASCO, 2018. Hussain MH, MacVicar GR, Petrylak DP, et al. Trastuzumab, paclitaxel, carboplatin, and gemcita-bine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: re-sults of a multicenter phase Ⅱ National Cancer Institute trial[J]. J Clin Oncol, 2007, 25(16):2218-2224. Oudard S, Culine S, Vano Y, et al. Multicentre ran-domised phase Ⅱ trial of gemcitabine ＋ plati-num, with or without trastuzumab, in advanced or metastatic urothelial carcinoma overexpressing Her2[J]. Eur J Cancer, 2015, 51(1):45-54. Wülfing C, Machiels JP, Richel DJ, et al. A sin-gle-arm, multicenter, open-label phase 2 study of lapatinib as the second-linetreatment of patients with locally advanced or metastatic transitional cell carcinoma[J]. Cancer, 2009, 115(13):2881-2890. Powles T, Huddart RA, Elliott T, et al. Phase Ⅲ , Double-Blind, Randomized Trial That Compared Maintenance Lapatinib Versus Placebo After First-Line Chemotherapy in Patients With Human Epidermal Growth Factor Receptor 1/2-Positive Metastatic Bladder Cancer[J]. J Clin Oncol, 2017, 35(1):48-55. Choudhury NJ, Campanile A, Antic T, et al. Afat-inib Activity in Platinum-Refractory Metastatic Urothelial Carcinoma in Patients With ERBB Al-terations[J]. J Clin Oncol, 2016, 34(18):2165-2171. Rosa Nadal. Clinical efficacy of cabozantinib plus nivolumab (CaboNivo) and CaboNivo plus ipili-mumab (CaboNivoIpi) in patients (pts) with chem-otherapy-refractory metastatic urothelial carcinoma (mUC) either naıve (n) or refractory (r) tocheck-point inhibitor (CPI)[C]. Chicago: ASCO, 2018